Replacing animal testing with synthetic cell scaffolds

February 11, 2020

In the field of cancer research, the idea that scientists can disrupt cancer growth by changing the environment in which cancerous cells divide is growing in popularity. The primary way researchers have tested this theory is to conduct experiments using animals.

Smitha Rao's cell scaffolding research aims to replace animal testing in cancer research with electrospun synthetics.

Rao, assistant professor of biomedical engineering at Michigan Technological University, recently published "Engineered three-dimensional scaffolds modulating fate of breast cancer cells using stiffness and morphology related cell adhesion" in the journal IEEE Open Journal of Engineering in Medicine and Biology.

Rao's coauthors are doctoral student Samerender Hanumantharao, master's student Carolynn Que and undergraduate student Brennan Vogl, all Michigan Tech biomedical engineering students.

Standardizing with Synthetics

When cells grow inside the body, they require something known as an extra-cellular matrix (ECM) on which to grow, just like a well-built house requires a strong foundation. To study how cells grow on ECMs, researchers need to source the matrices from somewhere.

"Synthetic ECMs are created by electrospinning matrices from polymers such as polycaprolactone and are more consistent for research than using cells from different kinds of animals," Hanumantharao said.

"In my lab the focus has been on standardizing the process and using synthetic materials to keep the same chemical formulation of a scaffold, but change the physical structure of the fibers that are produced," Rao said, noting that changing the type of polymer or adding solvents to polymers introduces too many variables, which could affect the way cells grow on the scaffolds. Rao and her fellow researchers, therefore, can compare separate cell lines with different scaffold alignments by changing just one aspect of the experiment: voltage.

By changing the voltage at which the polymer is spun, the researchers can alter the shape of the scaffolds, whether honeycombed, mesh or aligned. Rao's team published recently in Royal Chemistry Society Advances about manipulating electric fields to achieve different scaffold patterns. Rao's team is working with Dipole Materials to explore scaling up the process.

Rao and her fellow researchers used four different cell lines to test the efficacy of the electrospun scaffolds: 184B5, which is normal breast tissue, as a control; MCF-7, a breast adenocarcinoma; MCF10AneoT, a premalignant cell line; and MDA-MB-231, a triple negative adenocarcinoma-metastatic, a very difficult-to-detect cancer.

"We can study why and how cancer cells metastasize," Rao said. "We can understand in a true 3D system why pre-metastatic cells become metastatic, and provide tools to other researchers to study signaling pathways that change between pre-malignant and malignant cells."

Avenues for Future Research

In addition, the research has uncovered information for another area of study: In what type of cellular environment do malignant cancer cells grow best? Rao's group discovered that the triple-negative breast cancer cells preferred honeycomb scaffolds while adenocarcinoma cells favored mesh scaffolds and premalignant cells preferred the aligned scaffolds. In the future, scientists may be able to engineer cell scaffolding--stiffness, structure and shape--to make the area around a tumor in a person's body a far less hospitable place for cancer cells to grow.

Michigan Technological University

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to